Search results

This work analyzes a pharmaceutical supply chain (PSC) in terms of supply chain visibility (SCV). The current good distribution practice (GDP) guideline demands increased visibility from firms. The purpose of this paper is to propose a solution for SCV enhancements based on automatic identification (Auto-ID) technologies.

The authors qualitatively analyze data from ten case studies of actors in a PSC. A review of Auto-ID technologies supports the derivation of solutions to enhance SCV.

This work shows that the functionalities of Auto-ID technologies offered by current practical monitoring solutions and challenges created by the GDP guideline necessitate further SCV enhancements. To enhance SCV, the authors propose three solutions: securPharm with passive radio frequency identification tags, transport containers with sensor nodes, and an SCV dashboard.

This study is limited to a PSC in Germany and is therefore not intended to be exhaustive. Thus, the results serve as a foundation for further analyses.

This study provides an overview of the functionality of Auto-ID technologies. In juxtaposition with the influence of the GDP guideline, the use of our Auto-ID-based solutions can help to enhance SCV.

This work analyzes a PSC in Germany, with consideration given to the influence of current legislation. Based on a multiple-case-study design, the authors derive three Auto-ID-based solutions for enhancing SCV.

The purpose of this paper is to examine the pharmaceutical supply chain for artemisinin‐based combination therapies (ACT) in Ghana.

This study employed an inductive approach in examining the dynamics of the pharmaceutical supply chain. The study also used analytical hierarchical process in identifying factors that are detrimental to the ACT supply chain.

The study revealed that there are basically two main supply channels through which ACT enters the Ghanaian pharmaceutical system – private and public. The ACT network depicts a strong evidence of actor interdependence and long‐term relationships. However, the key supply chain enabler – the use of information technology – was found to be lacking, leading to delays and disruptions in the supply chain system. Disruption was found to be the main detrimental factor to the supply chain although delay was found to be occurring more frequently. Price increases indicated a low effect on the supply network at the pharmacy level, but the general price of the highly subsidised effective ACT (Coartem) remains very high.

Owing to constraints in accessibility, it was challenging to contact all the actors in the network individually, especially the consumer. Drugs considered in the study were the WHO approved ACT, even though efforts were made to compile available anti‐malarial drugs on the market.

This study has provided insights into the supply chain for ACT. The findings of the study are relevant in improving the supply chain system.

The paper brings to the fore the need for a proper pharmaceutical supply chain management in the health sector with regards to one of the world's most infectious and deadly diseases – malaria.

A key feature of human rights in health is access to safe, effective and affordable medicines. Pharmacovigilance is advocated for monitoring intended/unintended effects of medicines to assure their safety. The purpose of this paper is to synthesize knowledge about supply chain impediments to safe medicines in developing nations and contribute to future development of research in this field.

This paper conducts a structured literature review based on Preferred Reporting Items for the Systematic Reviews and Meta-Analyses guidelines. It aims at profiling supply chain impediments to safe medicines in developing nations by reviewing 46 recent pharmacovigilance-specific papers published between 2005 and 2020.

Analysis of reviewed articles identified criticality of supply chain impediments that affect constituents across pharmaceutical in developing nations, which still struggle to maintain robust national pharmacovigilance systems due to lack of awareness, policy and practices.

Research results can be applied by pharmaceutical industry decision-makers and drug safety professionals in developing nations. Because the review is qualitative in nature, its implication ought to be tested after actual implementation.

This review can help identify underinvestigated impediments and methods to aid in developing new pharmacovigilance knowledge areas in developing nation context.

The review uncovers gaps in global health equity dialogue in developing nations. It also recognizes that macrolevel supply chain impediments exist due to unfair disease burden and health inequities in developing nations.

The paper examines supply chain impediments to safe medicines in developing nations with insights for future pharmacovigilance research. Identifying and classifying supply chain impediments through this review is the first step toward creating effective interventions for these impediments to safe medicines.

Antibiotics shortages have become an increasingly common problem in Europe because of several reasons, including the offshoring of the production of active pharmaceutical ingredients for many of these products to low production cost countries, such as China and India. The problem has deteriorated because of the Covid-19 crisis that has put most global value chains (GVCs) under great stress. This situation has boosted extensive discussions among academics, practitioners and policymakers on possible changes to the configuration of GVCs. This paper aims to focus specifically on antibiotics supply chains from the perspective of a small country (Sweden), and analyse the pros and cons of backshoring and nearshoring alternatives, as a means to reduce drug shortages.

This work adopts a systemic perspective to capture the implications of reshoring for the different stakeholders involved in the antibiotics field. The present meso-analysis, focusing at the industry level, is based on multiple sources of primary data collected between 2014 and 2021, including participation in policy-related projects and interviews with over 100 representatives of key stakeholders in the antibiotics field.

This paper shows how reshoring can address the problems of drug shortages and reduce availability risk in antibiotics’ GVCs. However, the authors show that no simple and best solution exists because both alternatives of reshoring, i.e. backshoring and nearshoring, entail pros and cons for different stakeholders. The authors conclude with implications for policymakers and managers.

The analysis of pros and cons of both backshoring and nearshoring for various stakeholders offers relevant implications for research on operations and supply management, international business and economics/political science.

This paper looks at reshoring as a policy-driven decision and provides an innovative systemic perspective to analyse the implications for different stakeholders of two reshoring options concerning the antibiotics supply chain.

The purpose of this paper is to suggest the use of reverse medical supply chain data to infer changes of a population's health status with regard to a focal disease. It includes a detailed illustration of how health status information can be obtained from drug reverse chains.

A Bayesian dynamical model linking drug reverse supply chain data to relevant health status indicators with regard to a focal disease is developed. A detailed implementation of the model on computer‐simulated data is considered. The predictive ability of the methodology is also assessed using out‐of‐sample Monte Carlo‐based predictive analysis.

The results substantiate the good fit of the model to the empirical data.

Difficulty in obtaining actual return data and in selecting appropriate health status indicators. The correspondence disease‐drug is typically not one‐to‐one. Experts' opinion is required in setting up suitable mixing weights as many drugs may inform the health status relative to a given disease and vice versa.

Reverse logistics data may contain potential information, and this is not exclusive to medical chains.

The paper's suggestions tend to reinforce the notion that supply chain data may be used in many unsuspected settings. Solutions to issues of immediate concern in public health require multidisciplinary cooperation, and this paper shows how supply chain management can contribute. It is believed that the potential of reverse chain data in the health status prospect has previously hardly ever been pointed out.

Uganda is one of many African countries struggling to develop adequate healthcare, particularly in regard to local treatment and access to drugs. The purpose of this paper is to contribute to the understanding of how reducing supply‐chain complexity can improve health in developing countries.

This study and evaluation included 50 interviews and 27 site visits of the public healthcare system in Karamoja, northeast Uganda. A mapping of drug‐supply chains was undertaken to identify causes of stock shortages and possible solutions. A model for logistics process redesign was used for the analysis. Results were quantified with use of a simple tool developed for this specific purpose.

The main conclusion is that less supply‐chain complexity can produce higher customer service in terms of less stock shortages, while keeping costs down. By reducing lead times and uncertainty, increasing order frequencies, and moving order points and safety stocks, there may be better integration between information and goods flows and bottlenecks in the supply chain may be reduced.

While the empirical study is extensive, there are uncertainties in the data that must be taken into account. The effects of the suggested solutions remain to be analyzed and documented upon implementation.

The study was rooted in a practical problem and provides practical solutions for developing countries and agencies providing aid.

Stock shortages of life‐saving drugs are a general problem in countries with lack of financial and technical infrastructure. Improvements will impact the lives of many people.

The paper provides an understanding of the applicability of traditional logistics principles in a new context. It provides the academic community with a much‐needed in‐depth understanding of humanitarian logistics. The approach can be used in other studies.

The requirement of high-quality government-supported healthcare services has necessitated the significance of recognizing new management practices to enhance patient satisfaction. Hence, the purpose of this study is to address the patient's enhanced custom needs through the implementation of supply chain value stream mapping (SCVSM) in government-supported drug distribution system (DDS) for enhanced patient's satisfaction.

This study elucidates the role of one popular emerging management technique (i.e. SCVSM) in the healthcare sector by an investigative case study. The DDS in Rajasthan (India) was selected for this study. The data for this analysis were gathered in three ways (i.e. direct observation, documentary analysis and semi-structured interviews).

The outcome of this current study reveals that it is possible to apply the tool (SCVSM) to investigate the wastes in DDS to deliver the medicines at right time, right quantity and right quality. The application of SCVSM concluded that the various Kaizens (areas needed to improve) in lead time; transportation and routing should be adopted. The study further implemented kaizen on the current SCVSM and developed future SCVSM.

Although various stages and functions exist in the healthcare supply chain, the current study is focused on the distribution system of drugs. The proposed approach provides a platform for both researchers and academicians to understand the existing DDS and to implement the SCVSM approach in the healthcare environment. The results show that the proposed SCVSM model is able to identify some operational bottlenecks and wastes which interfere in DDS.

It was observed that limited literature related to lean implementation on DDS and implementation of SCVSM on the healthcare environment in general and government-supported or public in specific are available. The current study on the application of SCVSM in DDS is unique in nature and will definitely add value to the existing literature of the application of value stream mapping (VSM) on the healthcare supply chain management field.

The aim of this paper is to analyze the pharmaceutical supply chain using the DMAIC process for improvement of the reverse logistics in a recall to avert the possibility of harm to a consumer.

A framework is used for guiding one towards the responsibilities of the different organizations concerning reverse logistics. This is further developed into a Cause and Effect analysis, performed on the supply chain and the hypothesized problem areas. Improvement concepts were then considered in the use of RFID, consistent information systems and transportation carriers to streamline the supply chain and reducing the risk of counterfeit drugs entering the forward supply chain. FMEA is used to understand the failure modes and the severity of the respective failures in the reverse logistics supply chain.

The study yielded interesting and innovative solutions being tested and conceived at the present time, but specific information on the pharmaceutical supply chain was limited. The majority of the reverse logistics for pharmaceuticals is handled through third‐party providers, and therefore this specific knowledge is well guarded, being a core competency.

The improvement concepts were found to have managerial impacts such as improved communication flow, and dedicated group(s) to focus on the reverse logistics to remove miscommunication and perception errors. The ability to make improvements, as well as sustain the improvements, will also require significant and consistent management support.

The study is a first look at the forward and reverse logistics processes for the pharmaceutical industry supply chain and analysis of potential improvements utilizing DMAIC process. It helps in understanding gaps, suggests measures to reduce them and provides direction for improvements related to the quality of service existing between logistics users, logistics service provider, pharmaceutical firm and customers. The methods of analysis used can also be utilized as a diagnostic tool to understand the weaknesses in the existing supply chain and thus help in identifying the key areas for improvements within the organization.

This paper aims to provide an integrated production-routing model in a three-echelon supply chain containing a two-layer transportation system to minimize the total costs of production, transportation, inventory holding and expired drugs treatment. In the proposed problem, some specifications such as multisite manufacturing, simultaneous pickup and delivery and uncertainty in parameters are considered.

At first, a mathematical model has been proposed for the problem. Then, one possibilistic model and one robust possibilistic model equivalent to the initial model are provided regarding the uncertain nature of the model parameters and the inaccessibility of their probability function. Finally, the performance of the proposed model is evaluated using the real data collected from a pharmaceutical production center in Iran. The results reveal the proper performance of the proposed models.

The results obtained from applying the proposed model to a real-life production center indicated that the number of expired drugs has decreased because of using this model, also the costs of the system were reduced owing to integrating simultaneous drug pickup and delivery operations. Moreover, regarding the results of simulations, the robust possibilistic model had the best performance among the proposed models.

This research considers a two-layer vehicle routing in a production-routing problem with inventory planning. Moreover, multisite manufacturing, simultaneous pickup of the expired drugs and delivery of the drugs to the distribution centers are considered. Providing a robust possibilistic model for tackling the uncertainty in demand, costs, production capacity and drug expiration costs is considered as another remarkable feature of the proposed model.

The study aims to provide insights into the availability of common drugs with respect to disease load, regarding three common childhood diseases, acute respiratory infection (ARI), diarrhoea and malaria. The study flags an important issue regarding the level of expertise of the present system to address humanitarian logistics in case of emergency.

A mixed‐method approach using both qualitative and quantitative study techniques was used to collect data. Hospital level data were collected from randomly selected primary health centers and community health centers. a cohort of three community health centers and nine primary health centers were selected for the study. The data collected were both on disease load and availability of drugs during the study period (2009‐2012), using a retrospective cohort. Expert interviews were conducted of practising medical practitioners on classification of drugs into Vital, Essential and Desirable categories.

Results show that the month of September represents the highest morbidity (case loads of all three diseases taken together). Acute respiratory infection is most prevalent among the three diseases, with total case loads of 1,539 cases during the month of September (during 2009‐2012). However the Vital and Essential drugs availability for acute respiratory infection was found to be 7 per cent, 57 per cent for malaria and 98 per cent for diarrhoea. Drug supply was not only inadequate but also uneven and erratic, having weak correlation with the pattern of disease morbidity.

Cases who attended the government‐owned health centres were only considered for the study and it did not consider those who were attended by private practitioners. The study did highlight the capability of the system to manage ongoing health supplies and the extent of vulnerability it can pose in case of any humanitarian crisis but the latter remains outside the scope of the present study.

The study adds to the existing body of literature by demonstrating the gap that exists in availability of drugs against requirement, for common childhood illness. The study provides health policy makers with a useful guide to establish drugs requirement based on disease load, which holds policy implications across other low and middle income countries as well.